[{"id":"e17de7f3-6ed2-44ac-8c1d-acf78b25a29e","acronym":"NCI-2017-02296","url":"https://clinicaltrials.gov/study/NCT03375307","created_at":"2021-01-18T16:39:30.359Z","updated_at":"2025-02-25T13:39:36.028Z","phase":"Phase 2","brief_title":"Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes","source_id_and_acronym":"NCT03375307 - NCI-2017-02296","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC","pipe":" | ","alterations":" FANCG mutation","tags":["TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FANCG mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 11/03/2020","start_date":" 11/03/2020","primary_txt":" Primary completion: 12/16/2025","primary_completion_date":" 12/16/2025","study_txt":" Completion: 12/16/2025","study_completion_date":" 12/16/2025","last_update_posted":"2025-02-21"},{"id":"938d3f31-19a2-4d93-b968-94fc075d0fd5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03936465","created_at":"2021-01-18T19:23:12.104Z","updated_at":"2024-07-02T16:35:13.440Z","phase":"Phase 1","brief_title":"Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer","source_id_and_acronym":"NCT03936465","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MYC • MYCN • BRD4 • BRD3","pipe":" | ","alterations":" MYCN amplification","tags":["MYC • MYCN • BRD4 • BRD3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezobresib (BMS-986158) • trotabresib (BMS-986378)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 09/27/2019","start_date":" 09/27/2019","primary_txt":" Primary completion: 07/16/2024","primary_completion_date":" 07/16/2024","study_txt":" Completion: 07/16/2024","study_completion_date":" 07/16/2024","last_update_posted":"2024-03-21"},{"id":"522c49af-78dd-4744-a59b-263e97c777c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05019716","created_at":"2021-08-25T14:53:05.366Z","updated_at":"2024-07-02T16:35:16.121Z","phase":"Phase 1/2","brief_title":"Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma","source_id_and_acronym":"NCT05019716","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRD4 • NUTM1","pipe":"","alterations":" ","tags":["BRD4 • NUTM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • etoposide IV • ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-06"},{"id":"605feb5a-a612-4396-ba99-5fad946a9ff5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04116359","created_at":"2021-01-18T20:07:15.394Z","updated_at":"2024-07-02T16:36:40.639Z","phase":"Phase 1/2","brief_title":"Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma","source_id_and_acronym":"NCT04116359","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRD4 • NUTM1","pipe":"","alterations":" ","tags":["BRD4 • NUTM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • etoposide IV • molibresib (GSK525762)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/18/2020","start_date":" 09/18/2020","primary_txt":" Primary completion: 09/18/2020","primary_completion_date":" 09/18/2020","study_txt":" Completion: 09/18/2020","study_completion_date":" 09/18/2020","last_update_posted":"2020-09-28"}]